Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature
Open Access
- 9 November 2022
- journal article
- review article
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 16 (1) , 1-8
Abstract
Background: Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. Case presentation: Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed. Conclusions: This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management.Keywords
This publication has 31 references indexed in Scilit:
- Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizuresNeurology Neuroimmunology & Neuroinflammation, 2015
- Immune therapy in autoimmune encephalitis: a systematic reviewExpert Review of Neurotherapeutics, 2015
- Natural course of LGI1 encephalitis: 3–5years of follow-up without immunotherapyJournal of the Neurological Sciences, 2014
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013
- Rituximab associated neutropenia: Description of three cases and an insight into the underlying pathogenesisMedical Science Monitor, 2011
- Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitisAnnals of Neurology, 2010
- Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case seriesThe Lancet Neurology, 2010
- Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotoniaBrain, 2010
- Effect of Rituximab on the Peripheral Blood and Cerebrospinal Fluid B Cells in Patients With Primary Progressive Multiple SclerosisArchives of Neurology, 2005
- Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: A ReviewEpilepsia, 1994